Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Radiation Therapy (XRT) Clear all

Conditions: Malignant Glioma, Glioblastoma, Gliosarcoma
Interventions: Bevacizumab, Temozolomide, Radiation Therapy (XRT), Topotecan; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma, Adult
Interventions: NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT); Device · Drug · Radiation
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Brain Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • Houston, Texas

Conditions: Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 77
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions: Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pancreatic Cancer
Interventions: Cetuximab, Gemcitabine, Oxaliplatin, Capecitabine, Radiotherapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Paclitaxel, Radiation Therapy; Drug · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: ZD6474 (ZACTIMA), Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SABR); Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Delayed Breast Reconstruction; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Colorectal Cancer, Pain
Interventions: Capecitabine, Celecoxib, Radiation Therapy, Placebo; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more

Conditions: Non-small Cell Lung Cancer, Brain Cancer
Interventions: Tarceva (Erlotinib hydrochloride), Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 2
States / cities: Tucson, Arizona • Houston, Texas

Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis
Interventions: Accelerated Proton Beam Radiation Therapy (PBT), Accelerated Photon Radiation Therapy (XRT); Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg, XRT 10Gy x2; Biological · Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer, Oligometastatic Disease
Interventions: Prostate radiation (XRT), Systemic Therapy, Stereotactic ablative radiation therapy (SABR); Radiation · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 10
States / cities: La Jolla, California • Kansas City, Kansas • Baltimore, Maryland + 6 more

Conditions: Lung Cancer
Interventions: Celecoxib, Cisplatin, CPT-11, Concurrent Thoracic Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Biopsy, Niraparib, Prednisone, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: CT Scans, Implanted markers, Radiation Treatment (RT); Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Pd-103 with 20 vs 44 Gy supplemental beam XRT; Procedure
Lead sponsor: VA Puget Sound Health Care System; Federal
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Interventions: Murine CART19; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 0 Years to 29 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2037
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acetabular Fracture, Heterotopic Ossification
Interventions: External Beam Radiation (XRT), Debridement; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoma
Interventions: Bevacizumab, Doxorubicin, Radiation Therapy; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma Multiforme, Astrocytoma, Grade III, Anaplastic Ependymoma, Clear Cell Ependymoma, Ependymoma
Interventions: Heat Shock Protein Peptide Complex-96 (HSPPC-96), Tumor Resection, Radiation; Biological · Procedure · Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy; Radiation · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients

Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Delayed-Delayed Breast Reconstruction

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Ultrahypofractionation and Normal Tissue Toxicity

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

TERPS Trial for de Novo Oligometastic Prostate Cancer

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials

High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer

Orphan Indications for CD19 Redirected Autologous T Cells

Heterotopic Ossification Prophylaxis

Bevacizumab/Doxorubicin/Radiation for Sarcoma

Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma